Cancer-Associated Fibroblast Density, Prognostic Characteristics, and Recurrence in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
CAF
alpha-smooth muscle actin
cancer-associated fibroblasts
head and neck squamous cell carcinoma
myofibroblast
prognosis
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
05
2020
accepted:
27
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
The progression and clinical course of head and neck squamous cell carcinoma (HNSCC) relies on complex interactions between cancer and stromal cells in the tumor microenvironment (TME). Among the most abundant of these stromal cells are cancer-associated fibroblasts (CAFs). While their contribution to tumor progression is widely acknowledged, and various CAF-targeted treatments are under development, the relationship between CAF density and the clinicopathologic course of HNSCC has not been clearly defined. Here we examine the published evidence investigating the relationship of cancer-associated fibroblasts to local recurrence and indicators of prognostic significance in HNSCC. We conducted a meta-analysis of existing publications that compare the relationship between CAF density, local recurrence, and clinically significant pathologic criteria of disease development (T stage, nodal positivity, clinical stage, vascular invasion, perineural invasion, Ki67 expression, and differentiation). Thirteen studies met the selection criteria, providing a total study population of 926 patients. Forest plots and risk ratios were generated to illustrate overall relationships. Higher CAF density within the tumor microenvironment is associated with advanced T stage, nodal infiltration, clinical stage, vascular invasion, perineural invasion, Ki67 expression, and differentiation (p <0.05). High CAF density is also associated with increased rates of local recurrence (p <0.001). Across multiple studies, increased CAF density is correlated with histopathological criteria of poor prognosis in HNSCC. These findings highlight that CAFs may play a pivotal role in HNSCC development and progression. Staining for CAFs may represent a valuable addition to current pathologic analysis and help to guide prognosis and treatment. Understanding the mechanisms by which CAFs reciprocally interact with cancer cells will be crucial for optimization of TME-focused treatment of HNSCC.
Identifiants
pubmed: 33330034
doi: 10.3389/fonc.2020.565306
pmc: PMC7729160
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
565306Informations de copyright
Copyright © 2020 Knops, South, Rodeck, Martinez-Outschoorn, Harshyne, Johnson, Luginbuhl and Curry.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Adv Med Sci. 2015 Sep;60(2):264-72
pubmed: 26057860
Oncogene. 2018 Jan 11;37(2):160-173
pubmed: 28892046
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
J Oral Pathol Med. 2017 May;46(5):353-358
pubmed: 27681951
Semin Cell Dev Biol. 2010 Feb;21(1):33-9
pubmed: 19896548
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Oral Dis. 2020 May;26(4):733-744
pubmed: 31179584
Int J Oral Maxillofac Surg. 2015 Sep;44(9):1075-80
pubmed: 26055525
Oral Oncol. 2008 May;44(5):509-17
pubmed: 17826300
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Oral Oncol. 2019 Jun;93:66-75
pubmed: 31109698
Int J Cancer. 1988 May 15;41(5):707-12
pubmed: 2835323
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Int J Clin Exp Med. 2015 Feb 15;8(2):1896-903
pubmed: 25932118
Clin Transl Radiat Oncol. 2020 Apr 13;22:90-97
pubmed: 32337377
Annu Rev Biomed Eng. 2014 Jul 11;16:321-46
pubmed: 25014786
Am Soc Clin Oncol Educ Book. 2018 May 23;38:505-514
pubmed: 30231400
Nat Cell Biol. 2007 Dec;9(12):1392-400
pubmed: 18037882
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Mol Cancer Res. 2019 Sep;17(9):1893-1909
pubmed: 31239287
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Histopathology. 2007 Dec;51(6):849-53
pubmed: 18042073
Int J Cancer. 1991 Apr 1;47(6):843-6
pubmed: 2010226
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Pak Med Assoc. 2018 Jul;68(7):1115-1119
pubmed: 30317316
Exp Cell Res. 2012 Aug 1;318(13):1517-27
pubmed: 22516051
Oncotarget. 2017 Jan 31;8(5):8633-8647
pubmed: 28052009
Cell Cycle. 2012 Aug 15;11(16):3019-35
pubmed: 22874531
Cancers (Basel). 2019 Mar 28;11(4):
pubmed: 30925774
South Asian J Cancer. 2014 Jul;3(3):159-62
pubmed: 25136522
J Craniomaxillofac Surg. 2018 Apr;46(4):605-610
pubmed: 29439841
Oncol Rep. 2019 Oct;42(4):1319-1328
pubmed: 31364748
Cell Adh Migr. 2012 May-Jun;6(3):231-5
pubmed: 22568983
J Exp Clin Cancer Res. 2016 Nov 25;35(1):181
pubmed: 27884164
Cancer Sci. 2019 May;110(5):1790-1803
pubmed: 30843645
Cancers (Basel). 2013 Jan 31;5(1):149-69
pubmed: 24216702
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
Med Oral Patol Oral Cir Bucal. 2020 Mar 1;25(2):e268-e276
pubmed: 31967978
Med Oncol. 2012 Jun;29(2):690-703
pubmed: 21380786
Nat Rev Cancer. 2007 Feb;7(2):139-47
pubmed: 17218951
Tumour Biol. 2017 May;39(5):1010428317705512
pubmed: 28475003
Oral Oncol. 2007 Nov;43(10):999-1006
pubmed: 17257886
J Oral Pathol Med. 2018 May;47(5):443-453
pubmed: 28782893
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Br J Cancer. 2014 Feb 4;110(3):724-32
pubmed: 24335925
J Pathol. 2011 Mar;223(4):470-81
pubmed: 21294121
J Oral Pathol Med. 2014 May;43(5):335-43
pubmed: 24313357
Nat Genet. 2017 May;49(5):708-718
pubmed: 28319088
Oral Oncol. 2011 Jan;47(1):33-8
pubmed: 21112238
Carcinogenesis. 2018 Feb 9;39(2):170-179
pubmed: 29140428
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Lab Invest. 2019 Jun;99(6):777-792
pubmed: 30683902
Oral Oncol. 2013 May;49(5):381-6
pubmed: 23357526
Nat Med. 2011 Mar;17(3):320-9
pubmed: 21383745
J Oral Pathol Med. 2017 Jan;46(1):21-30
pubmed: 27229731
J Exp Clin Cancer Res. 2018 Jul 5;37(1):137
pubmed: 29976244
Cancer Res. 2018 Jul 15;78(14):3769-3782
pubmed: 29769197
J Cell Biochem. 2007 Jul 1;101(4):805-15
pubmed: 17226777
Semin Cancer Biol. 2014 Apr;25:47-60
pubmed: 24486645
Head Neck. 2009 Oct;31(10):1346-53
pubmed: 19373786
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
J Oral Pathol Med. 2009 Sep;38(8):639-43
pubmed: 19473444
Semin Oncol. 2014 Apr;41(2):217-34
pubmed: 24787294
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
J Oral Pathol Med. 2012 Jul;41(6):444-51
pubmed: 22296275
Pathol Res Pract. 1996 Jul;192(7):712-7
pubmed: 8880872
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Cell Metab. 2012 Jan 4;15(1):4-5
pubmed: 22225869
Br J Cancer. 2004 Feb 23;90(4):822-32
pubmed: 14970860
Cell Cycle. 2013 May 1;12(9):1371-84
pubmed: 23574725
Cancers (Basel). 2015 Feb 27;7(1):382-406
pubmed: 25734659
Cancer Immunol Immunother. 2015 Nov;64(11):1407-17
pubmed: 26201938
Immunol Res. 2012 Dec;54(1-3):266-74
pubmed: 22454102